Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
The purpose of this study is to compare progression free survival for SU011248 [sutent
 (sunitinib malate)] versus standard of care therapy in patients with previously treated,
 advanced, triple receptor negative (ER, PR, HER2) locally recurrent or metastatic breast
 cancer.
Inclusion Criteria:

 -  Recurrent or metastatic breast cancer

 -  Estrogen receptor (ER), progestin receptor (PR) and HER2/neu receptor (HER2) negative
 status

 -  Prior treatment with an anthracycline and a taxane in the adjuvant or advanced disease
 setting

 -  Relapse following adjuvant chemotherapy within 6 months of last treatment and/or
 received one or two chemotherapy regimens for advanced disease

 Exclusion Criteria:

 -  More than two chemotherapy regimens for advanced disease

 -  Uncontrolled/symptomatic spread of cancer to the brain